170 related articles for article (PubMed ID: 12692785)
1. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
2. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
3. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostate cancer is associated with low serum testosterone levels.
Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
[TBL] [Abstract][Full Text] [Related]
7. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
8. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
[TBL] [Abstract][Full Text] [Related]
9. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
10. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
[TBL] [Abstract][Full Text] [Related]
11. Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men.
Raivio T; Tapanainen JS; Kunelius P; Jänne OA
J Androl; 2002; 23(6):919-21. PubMed ID: 12399539
[TBL] [Abstract][Full Text] [Related]
12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
13. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.
Dalais FS; Meliala A; Wattanapenpaiboon N; Frydenberg M; Suter DA; Thomson WK; Wahlqvist ML
Urology; 2004 Sep; 64(3):510-5. PubMed ID: 15351581
[TBL] [Abstract][Full Text] [Related]
14. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
16. Androgens and prostate cancer risk: a prospective study.
Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
[TBL] [Abstract][Full Text] [Related]
17. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
18. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.
Heikkilä R; Aho K; Heliövaara M; Hakama M; Marniemi J; Reunanen A; Knekt P
Cancer; 1999 Jul; 86(2):312-5. PubMed ID: 10421267
[TBL] [Abstract][Full Text] [Related]
19. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
20. Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men?
Vicentini FC; Botelho LA; Hisano M; Ebaid GX; Lucon M; Lucon AM; Srougi M
Urology; 2009 May; 73(5):1032-5. PubMed ID: 19286245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
